CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Ruxolitinib (Jakafi) — Coverage Criteria

Defines payer coverage criteria, authorization durations, and documentation requirements for ruxolitinib (Jakafi) across FDA‑approved and selected compendial oncology and hematology indications for members of the plan.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyRuxolitinib (Jakafi) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization; typical approvals are granted for 12 months with reauthorization contingent on improvement and no unacceptable toxicity or disease progression.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthstypical authorization period for covered indications

FDA + compendiaIndications covered when criteria met

Mutation testingdocumentation required

GVHD, CRSimmune/toxic indications

Coverage Criteria and Policy Scope

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered with criteria

Covered when ALL applicable indication-specific criteria are met.

FDA-approved indications: Member has one of the FDA-approved indications: intermediate- or high-risk myelofibrosis (including primary MF, post-PV MF, post-ET MF), polycythemia vera with inadequate response or intolerance to hydroxyurea, steroid-refractory acute graft-versus-host disease (age >= 12 years), chronic graft-versus-host disease after failure of one or two systemic therapies, or other FDA-listed indications.

Myelofibrosis: Authorization of 12 months may be granted for the treatment of myelofibrosis.

Accelerated/Blast Phase Myeloproliferative Neoplasms: Authorization of 12 months may be granted for treatment of accelerated phase or blast phase myeloproliferative neoplasms when used as a single agent or in combination with azacitidine or decitabine.

Polycythemia Vera: Member has had an inadequate response or intolerance to hydroxyurea or peginterferon alfa-2a; authorization of 12 months may be granted.

Graft-versus-host disease: For acute GVHD: member has steroid-refractory acute GVHD. For chronic GVHD: member has chronic GVHD and has failed at least one prior line of systemic therapy. Authorization of 12 months may be granted.

Ph-like B-cell ALL/LL (compendial): Authorization of 12 months may be granted for Ph-like B-cell ALL/LL when molecular testing confirms either a CRLF2 mutation or a mutation associated with activation of the JAK/STAT pathway.

Chronic Myelomonocytic Leukemia (CMML)-2: Authorization of 12 months may be granted for CMML-2 when used in combination with a hypomethylating agent.

T-cell disorders and aCML/MDS/MPN: Authorization of 12 months may be granted for T-cell large granular lymphocytic leukemia or symptomatic T-cell prolymphocytic leukemia as a single agent; authorization of 12 months may be granted for BCR-ABL negative aCML or MDS/MPN with neutrophilia as a single agent or in combination with a hypomethylating agent.

Essential Thrombocythemia: Authorization of 12 months may be granted for essential thrombocythemia in members who have had an inadequate response or loss of response to hydroxyurea, peginterferon alfa-2a, or anagrelide.

Myeloid/lymphoid neoplasms with eosinophilia: Authorization of 12 months may be granted for myeloid/lymphoid neoplasms with eosinophilia when testing confirms a JAK2 rearrangement (chronic or blast phase).

Cytokine Release Syndrome (CAR T-cell): Authorization may be granted for CAR T-cell-induced cytokine release syndrome that is refractory to high-dose corticosteroids and anti-IL-6 therapy.

Immune checkpoint inhibitor-related concomitant myositis and myocarditis: Authorization may be granted when ruxolitinib is used in combination with abatacept for immune checkpoint inhibitor-related concomitant myositis and myocarditis.

Continuation criteria: For MF, accelerated/blast MPN, PV, acute GVHD, chronic GVHD, and ET: reauthorization of 12 months may be granted when there is improvement in symptoms and no unacceptable toxicity. For other malignant indications (e.g., ALL/LL, aCML/MDS/MPN with neutrophilia, CMML-2, T-cell disorders, myeloid/lymphoid neoplasms with eosinophilia): reauthorization of 12 months may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

CRS/myositis/myocarditis continuation: All members (including new members) requesting continuation for cytokine release syndrome or concomitant myositis and myocarditis must meet all initial authorization criteria.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for all covered indications listed in this policy. Typical approvals are granted for up to 12 months for covered indications. Reauthorization/continuation of therapy may be granted for 12 months when the member demonstrates improvement or stability and has no unacceptable toxicity or disease progression, as specified by the indication.

Authorization decisions and durations: typically 12 months for covered indications
Reauthorization contingent on clinical improvement or stability and absence of unacceptable toxicity or disease progression

Step Therapy

Required Prior Therapies for PV and ET

For polycythemia vera and essential thrombocythemia, documentation must show the member had an inadequate response or intolerance to hydroxyurea (or peginterferon alfa‑2a where specified).

Polycythemia vera: inadequate response or intolerance to hydroxyurea or peginterferon alfa‑2a
Essential thrombocythemia: inadequate response or loss of response to hydroxyurea, peginterferon alfa‑2a, or anagrelide

Documentation Required

Molecular and Diagnostic Testing Documentation

Submission of the following documentation is necessary to initiate prior authorization review for specified indications: For Ph‑like B‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma, medical record documentation confirming either a CRLF2 mutation or a mutation activating the JAK/STAT pathway. For myeloid/lymphoid neoplasms with eosinophilia, testing or analysis confirming a JAK2 rearrangement.

Ph‑like B‑cell ALL/LL: documentation of CRLF2 mutation OR mutation activating JAK/STAT pathway
Myeloid/lymphoid neoplasms with eosinophilia: testing confirming JAK2 rearrangement

Denial Risk

Not Covered Outside Listed Indications

Use of this agent for indications not listed under the covered indications (i.e., all other indications) is considered experimental/investigational and is not medically necessary. Requests for uses outside the listed indications may be denied.

All indications not explicitly listed in the covered indications section are considered experimental/investigational and not medically necessary

Key Terms and Diagnostic Subtypes

inv-09: Ph-like B-cell ALL/LL — definition and requirements

DefinitionA B-cell acute lymphoblastic leukemia/lymphoblastic lymphoma subtype characterized by a CRLF2 mutation or other mutation that activates the JAK/STAT pathway.

Coverage requirementAuthorization may be granted for 12 months when molecular testing documents either a CRLF2 mutation or another JAK/STAT pathway–activating mutation.

Documentation to submitMedical record documentation confirming either a CRLF2 mutation or a mutation associated with activation of the JAK/STAT pathway is required to initiate prior authorization review.

inv-10: Myeloid/lymphoid neoplasms with eosinophilia — definition and requirements

DefinitionMyeloid/lymphoid neoplasms with eosinophilia that harbor JAK2 rearrangements.

Coverage requirementAuthorization may be granted for 12 months for chronic- or blast-phase disease when testing confirms a JAK2 rearrangement.

Documentation to submitTesting or analysis confirming JAK2 rearrangement must be provided for authorization consideration.

Molecular and Genetic Testing Requirements

inv-12: CRLF2 or other JAK/STAT pathway mutations — biomarker requirement

BiomarkerCRLF2 mutation (cytokine receptor-like factor 2).

Alternate biomarkersOther mutations associated with activation of the JAK/STAT pathway.

Documentation requirementMedical record documentation confirming CRLF2 or another JAK/STAT pathway–activating mutation is required to initiate prior authorization for Ph-like B-cell ALL/LL.

inv-13: JAK2 rearrangement — biomarker requirement

BiomarkerJAK2 rearrangement confirmed by testing or analysis.

Coverage linkageRequired for authorization of myeloid/lymphoid neoplasms with eosinophilia (chronic or blast phase).

Documentation requirementSubmit testing/analysis results confirming JAK2 rearrangement with the prior authorization request.

Clinical Background and Drug Overview

Ruxolitinib (Jakafi) is a selective JAK1/JAK2 inhibitor with FDA-approved indications that include treatment of myelofibrosis, polycythemia vera, and management of steroid-refractory acute and chronic graft-versus-host disease. The policy also recognizes multiple compendial hematologic malignancy and immune/toxic indications (for example, Ph-like B-cell ALL/LL, CMML-2, myeloid/lymphoid neoplasms with eosinophilia, CAR T-cell-related cytokine release syndrome, and immune checkpoint inhibitor-related concomitant myositis and myocarditis) where coverage may be considered when specific molecular or clinical criteria are met.

OpenPayer